Brokerages predict that Motus GI Holdings Inc (NASDAQ:MOTS) will post earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Motus GI’s earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.27). The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Motus GI will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.32) to ($1.12). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.04) to ($0.78). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Motus GI.
Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.01). The firm had revenue of $0.03 million for the quarter.
A number of analysts have recently issued reports on the stock. Oppenheimer set a $10.00 price objective on shares of Motus GI and gave the company a “buy” rating in a report on Wednesday, August 15th. LADENBURG THALM/SH SH assumed coverage on shares of Motus GI in a report on Thursday, August 30th. They issued a “buy” rating and a $14.50 price objective on the stock. Zacks Investment Research downgraded shares of Motus GI from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. Dougherty & Co assumed coverage on shares of Motus GI in a report on Tuesday, August 28th. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, ValuEngine upgraded shares of Motus GI from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $10.50.
NASDAQ MOTS opened at $5.24 on Tuesday. Motus GI has a 12-month low of $3.75 and a 12-month high of $10.66. The company has a market capitalization of $83.09 million and a PE ratio of -4.09.
Institutional investors and hedge funds have recently modified their holdings of the stock. IPG Investment Advisors LLC acquired a new position in Motus GI during the second quarter worth $106,000. Quantitative Systematic Strategies LLC acquired a new position in Motus GI during the second quarter worth $113,000. Hilltop Holdings Inc. acquired a new position in Motus GI during the first quarter worth $502,000. Finally, Highbridge Capital Management LLC acquired a new position in Motus GI during the first quarter worth $896,000. Institutional investors and hedge funds own 21.61% of the company’s stock.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Recommended Story: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.